Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Lam ET, et al. Among authors: olencki t. J Immunother. 2014 Sep;37(7):360-5. doi: 10.1097/CJI.0000000000000044. J Immunother. 2014. PMID: 25075565 Free PMC article.
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P, Sandstrom K, Tuason L, Rayman P, Tubbs R, McLain D, Klein E, Novick A, Finke J. Bukowski RM, et al. Among authors: olencki t. J Immunother. 1997 Jul;20(4):301-11. doi: 10.1097/00002371-199707000-00007. J Immunother. 1997. PMID: 9220320 Clinical Trial.
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd. Varker KA, et al. Among authors: olencki t. Clin Cancer Res. 2006 Oct 1;12(19):5850-8. doi: 10.1158/1078-0432.CCR-06-1159. Clin Cancer Res. 2006. PMID: 17020993
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE 3rd. Kondadasula SV, et al. Among authors: olencki t. Cancer Immunol Immunother. 2008 Aug;57(8):1137-49. doi: 10.1007/s00262-007-0444-7. Epub 2008 Jan 10. Cancer Immunol Immunother. 2008. PMID: 18193422 Free PMC article.
NCCN clinical practice guidelines in oncology: testicular cancer.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. Motzer RJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. doi: 10.6004/jnccn.2009.0047. J Natl Compr Canc Netw. 2009. PMID: 19555582 No abstract available.
NCCN clinical practice guidelines in oncology: kidney cancer.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. Motzer RJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. doi: 10.6004/jnccn.2009.0043. J Natl Compr Canc Netw. 2009. PMID: 19555584 No abstract available.
111 results